On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
-
REGULATORY Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026
-
REGULATORY Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
-
BUSINESS Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
-
BUSINESS Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
-
BUSINESS Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
-
ORGANIZATION EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
-
BUSINESS Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
-
BUSINESS Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
-
BUSINESS Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
-
COMMENTARY G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
-
BUSINESS Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
-
REGULATORY Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
-
BUSINESS Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
-
BUSINESS DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
-
REGULATORY Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
-
REGULATORY Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
-
BUSINESS Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
-
BUSINESS ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
-
COMMENTARY Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…